Cited by 177Treatment of Major DepressionNeuroscience and Neuropharmacology ResearchAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.

Riluzole in the Treatment of Mood and Anxiety Disorders

Pittenger, Christopher, Coric, Vladimir, Banasr, Mounira, Bloch, Michael, Krystal, John H, Sanacora, Gerard·2008·CNS Drugs

DOI 10.2165/00023210-200822090-00004

Open this paper in CoChat — free account

Abstract

Recent advances implicate amino acid neurotransmission in the pathophysiology and treatment of mood and anxiety disorders. Riluzole, which is approved and marketed for the treatment of amyotrophic lateral sclerosis, is thought to be neuroprotective through its modulation of glutamatergic neurotransmission. Riluzole has multiple molecular actions in vitro; the two that have been documented to occur at physiologically realistic drug concentrations and are therefore most likely to be clinically relevant are inhibition of certain voltage-gated sodium channels, which can lead to reduced neurotransmitter release, and enhanced astrocytic uptake of extracellular glutamate.Although double-blind, placebo-controlled trials are lacking, several open-label trials have suggested that riluzole, either as monotherapy or as augmentation of standard therapy, reduces symptoms of obsessive-compulsive disorder, unipolar and bipolar depression, and generalized anxiety disorder. In studies of psychiatrically ill patients conducted to date, the drug has been quite well tolerated; common adverse effects include nausea and sedation. Elevation of liver function tests is common and necessitates periodic monitoring, but has been without clinical consequence in studies conducted to date in psychiatric populations. Case reports suggest utility in other conditions, including trichotillomania and self-injurious behaviour associated with borderline personality disorder. Riluzole may hold promise for the treatment of several psychiatric conditions, possibly through its ability to modulate pathologically dysregulated glutamate levels, and merits further investigation.

Integrity signals

Registry

Crossref · 10.2165/00023210-200822090-00004

Cites

205 of 205 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A rating scale for depression
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
A new depression scale designed to be sensitive to change
Montgomery, S. A., & Åsberg, M. (1979) · British Journal of Psychiatry · doi:10.1192/bjp.134.4.382 · Cited by 13,962
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
A Rating Scale for Mania: Reliability, Validity and Sensitivity
Young, R. C., Biggs, J. T., Ziegler, V. E., & Meyer, D. A. (1978) · British Journal of Psychiatry · doi:10.1192/bjp.133.5.429 · Cited by 8,744
The Yale-Brown Obsessive Compulsive Scale: I. Development, Use, and Reliability
Goodman, W. K. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110048007 · Cited by 7,712
Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Glutamate uptake
Danbolt, N. C. (2001) · Progress in Neurobiology · doi:10.1016/s0301-0082(00)00067-8 · Cited by 4,227
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
The Synaptic Organization of the Brain
(2004) · Oxford University Press eBooks · doi:10.1093/acprof:oso/9780195159561.001.1 · Cited by 3,574
A Neurotrophic Model for Stress-Related Mood Disorders
Duman, R. S., & Monteggia, L. M. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.02.013 · Cited by 3,375

Show all 205 references

Research works printed but not linked: 13

Miller, 2007, Cochrane Database Syst Rev, &NA;, CD001447
Wahl, 1999, Acta Neurochir Suppl, 73, 103
Carlezon Jr, 2005, TINS, 28, 436
Marini, 2004, Restor Neurol Neurosci, 22, 121
Cluskey, 2001, Mol Path, 54, 386
McShane, 2006, Cochrane Database Syst Rev, &NA;, CD003154
Magistretti, 2006, JExp Biol, 209, 2304
Yanagisawa, 1997, Igakuno Ayumi, 182, 851
Seppi, 2001, JNeurol, 248, 866
Zarate Jr, 2002, Translational Neurosci, 36, 35
Goodman, 1989, Arch Gen Psychiatry, 46, 1106
Stewart, 2007, Am J Med Genet B Neuropsych Genet, 144, 1028
Lacomblez, 2002, Therapie, 57, 65

Sorted by citations

Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,526
Inflammation, glutamate, and glia: a trio of trouble in mood disorders
Haroon, E., Miller, A. H., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2016.199 · Cited by 584
Self-citation
The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology
Martin, E. I., Ressler, K. J., Binder, E. B., & Nemeroff, C. B. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.004 · Cited by 623
Glial pathology in an animal model of depression: reversal of stress-induced cellular, metabolic and behavioral deficits by the glutamate-modulating drug riluzole
Banasr, M., Chowdhury, G. M. I., Terwilliger, R., Newton, S. S., Duman, R. S., Behar, K. L., & Sanacora, G. (2010) · Molecular Psychiatry · doi:10.1038/mp.2008.106 · Cited by 458
Self-citation
Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders
Mantegazza, M., Curia, G., Biagini, G., Ragsdale, D. S., & Avoli, M. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70059-4 · Cited by 462
Bi-ancestral depression GWAS in the Million Veteran Program and meta-analysis in >1.2 million individuals highlight new therapeutic directions
Levey, D. F., Stein, M. B., Wendt, F. R., Pathak, G. A., Zhou, H., Aslan, M., Quaden, R., Harrington, K. M., Nuñez, Y. Z., Overstreet, C., et al. (2021) · Nature Neuroscience · doi:10.1038/s41593-021-00860-2 · Cited by 422
Self-citation
Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment
Pittenger, C., Bloch, M. H., & Williams, K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.09.006 · Cited by 426
Self-citation
A Review of the Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating Amyotrophic Lateral Sclerosis: What have we Learned in the Last Decade?: Neural Mechanisms of Action and Clinical Efficiency of Riluzole in Treating ALS
Bellingham, M. C. (2011) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2009.00116.x · Cited by 388
Neurological perspectives on voltage-gated sodium channels
Eijkelkamp, N., Linley, J. E., Baker, M. D., Minett, M. S., Cregg, R., Werdehausen, R., Rugiero, F., & Wood, J. (2012) · Brain · doi:10.1093/brain/aws225 · Cited by 355
Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial
Mathew, S. J., Murrough, J. W., Rot, M. A. H., Collins, K. A., Reich, D. L., & Charney, D. S. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000169 · Cited by 297
Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder
Duncan, W. C., Sarasso, S., Ferrarelli, F., Selter, J., Riedner, B. A., Hejazi, N. S., Yuan, P., Brutsche, N., Manji, H. K., Tononi, G., et al. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145712000545 · Cited by 256
An astroglial basis of major depressive disorder? An overview
Wang, Q., Jie, W., Liu, J., Yang, J., & Gao, T. (2017) · Glia · doi:10.1002/glia.23143 · Cited by 222
From Pathophysiology to Novel Antidepressant Drugs: Glial Contributions to the Pathology and Treatment of Mood Disorders
Sanacora, G., & Banasr, M. (2013) · Biological Psychiatry · doi:10.1016/j.biopsych.2013.03.032 · Cited by 239
Self-citation
Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C., & Bloch, M. H. (2014) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2014.05.006 · Cited by 222
Self-citation
Riluzole in patients with hereditary cerebellar ataxia: a randomised, double-blind, placebo-controlled trial
Romano, S., Coarelli, G., Marcotulli, C., Leonardi, L., Piccolo, F., Spadaro, M., Frontali, M., Ferraldeschi, M., Vulpiani, M. C., Ponzelli, F., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00201-x · Cited by 212
An Open-Label Trial of Riluzole, a Glutamate Antagonist, in Children with Treatment-Resistant Obsessive-Compulsive Disorder
Grant, P., Lougee, L., Hirschtritt, M., & Swedo, S. E. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0021 · Cited by 197
Riluzole in cerebellar ataxia
Ristori, G., Romano, S., Visconti, A., Cannoni, S., Spadaro, M., Frontali, M., Pontieri, F. E., Vanacore, N., & Salvetti, M. (2010) · Neurology · doi:10.1212/wnl.0b013e3181d31e23 · Cited by 199
Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies
Averill, L. A., Purohit, P., Averill, C. L., Boesl, M. A., Krystal, J. H., & Abdallah, C. G. (2016) · Neuroscience Letters · doi:10.1016/j.neulet.2016.11.064 · Cited by 198
Self-citation
Pharmacological treatment of anxiety disorders: Current treatments and future directions
Farach, F. J., Pruitt, L. D., Jun, J. J., Jerud, A. B., Zoellner, L. A., & Roy‐Byrne, P. (2012) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2012.07.009 · Cited by 202
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal, J. H., Mathew, S. J., DʼSouza, D. C., Garakani, A., Gunduz-Bruce, H., & Charney, D. S. (2010) · CNS Drugs · doi:10.2165/11533230-000000000-00000 · Cited by 180
Self-citation
New perspectives in glutamate and anxiety
Riaza Bermudo-Soriano, C., Perez-Rodriguez, M. M., Vaquero-Lorenzo, C., & Baca-Garcia, E. (2012) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.010 · Cited by 207
Recent Advances in the Chemistry and Biology of Benzothiazoles
Gill, R. K., Rawal, R. K., & Bariwal, J. B. (2015) · Archiv der Pharmazie · doi:10.1002/ardp.201400340 · Cited by 176
A new generation of antidepressants: an update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate/GABA neurotransmitter systems
Wilkinson, S. T., & Sanacora, G. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.007 · Cited by 173
Self-citation
The Neurobiology of Anxiety Disorders: Brain Imaging, Genetics, and Psychoneuroendocrinology
Martin, E. I., Ressler, K. J., Binder, E. B., & Nemeroff, C. B. (2010) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2010.07.006 · Cited by 176
The Glutamate Hypothesis in ALS: Pathophysiology and Drug Development
Blasco, H., Mavel, S., Corcia, P., & Gordon, P. H. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140916120118 · Cited by 165
Alzheimer Disease: Crosstalk between the Canonical Wnt/Beta-Catenin Pathway and PPARs Alpha and Gamma
Vallée, A., & Lecarpentier, Y. (2016) · Frontiers in Neuroscience · doi:10.3389/fnins.2016.00459 · Cited by 147
Ketamine as a new treatment for depression: A review of its efficacy and adverse effects
Katalinic, N., Lai, R., Somogyi, A. A., Mitchell, P. B., Glue, P., & Loo, C. K. A. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867413486842 · Cited by 132
Antidepressants act directly on astrocytes: Evidences and functional consequences
Czéh, B., & Benedetto, B. D. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.04.017 · Cited by 132
Glutamatergic Synaptic Dysfunction and Obsessive-Compulsive Disorder
Ting, J. T., & Feng, G. (2008) · Current Chemical Genomics · doi:10.2174/1875397300802010062 · Cited by 125
Pharmacotherapy of obsessive–compulsive disorder: evidence-based treatment and beyond
Fineberg, N. A., Reghunandanan, S., Brown, A., & Pampaloni, I. (2013) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867412461958 · Cited by 122
Action control is mediated by prefrontal BDNF and glucocorticoid receptor binding
Gourley, S. L., Swanson, A. M., Jacobs, A. M., Howell, J. L., Mo, M., Dileone, R., Koleske, A. J., & Taylor, J. R. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1208342109 · Cited by 119
Vesicular glutamate transporter mRNA expression in the medial temporal lobe in major depressive disorder, bipolar disorder, and schizophrenia
Uezato, A., Meador‐Woodruff, J. H., & McCullumsmith, R. E. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00752.x · Cited by 113
Autism Spectrum Disorder: Focus on Glutamatergic Neurotransmission
Montanari, M., Martella, G., Bonsi, P., & Meringolo, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073861 · Cited by 114
Roles of glutamate signaling in preclinical and/or mechanistic models of depression
Tokita, K., Yamaji, T., & Hashimoto, K. (2011) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2011.04.016 · Cited by 104
CO-OCCURRENCE OF ANXIETY AND BIPOLAR DISORDERS: CLINICAL AND THERAPEUTIC OVERVIEW
Vázquez, G. H., Baldessarini, R. J., & Tondo, L. (2014) · Depression and Anxiety · doi:10.1002/da.22248 · Cited by 94
An update on the role of glutamate in the pathophysiology of depression
Mitchell, N. D., & Baker, G. B. (2010) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2009.01529.x · Cited by 91
Targeting glial physiology and glutamate cycling in the treatment of depression
Valentine, G. W., & Sanacora, G. (2009) · Biochemical Pharmacology · doi:10.1016/j.bcp.2009.04.008 · Cited by 87
Self-citation
Glutamate Systems in DSM-5 Anxiety Disorders: Their Role and a Review of Glutamate and GABA Psychopharmacology
Nasir, M., Trujillo, D., Levine, J. L. S., Dwyer, J. B., Rupp, Z. W., & Bloch, M. H. (2020) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2020.548505 · Cited by 94
Self-citation
Riluzole rescues glutamate alterations, cognitive deficits, and tau pathology associated with P301L tau expression
Hunsberger, H. C., Weitzner, D. S., Rudy, C. C., Hickman, J. E., Libell, E. M., Speer, R. R., Gerhardt, G. A., & Reed, M. N. (2015) · Journal of Neurochemistry · doi:10.1111/jnc.13230 · Cited by 85
Riluzole Normalizes Early-Life Stress-Induced Visceral Hypersensitivity in Rats: Role of Spinal Glutamate Reuptake Mechanisms
Gosselin, R., O’Connor, R. M., Tramullas, M., Julio‐Pieper, M., Dinan, T. G., & Cryan, J. F. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.03.003 · Cited by 87
Review of the Use of the Glutamate Antagonist Riluzole in Psychiatric Disorders and a Description of Recent Use in Childhood Obsessive-Compulsive Disorder
Grant, P., Song, J. Y., & Swedo, S. E. (2010) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2010.0009 · Cited by 84
Negative allosteric modulation of metabotropic glutamate receptor 5 results in broad spectrum activity relevant to treatment resistant depression
Hughes, Z. A., Neal, S. J., Smith, D. L., Rizzo, S. J. S., Pulicicchio, C. M., Lotarski, S. M., Lu, S.-P., Dwyer, J. M., Brennan, J. A., Olsen, M. A., et al. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.04.007 · Cited by 85
Antidepressant-like properties of oral riluzole and utility of incentive disengagement models of depression in mice
Gourley, S. L., Espitia, J. W., Sanacora, G., & Taylor, J. R. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2403-4 · Cited by 89
Self-citation
The PSD-95/nNOS complex: New drugs for depression?
Doucet, M. V., Harkin, A., & Dev, K. K. (2011) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2011.11.005 · Cited by 84
Riluzole Augmentation in Treatment-Refractory Obsessive-Compulsive Disorder: A Pilot Randomized Placebo-Controlled Trial
Pittenger, C., Bloch, M. H., Wasylink, S., Billingslea, E., Simpson, R., Jakubovski, E., Kelmendi, B., Sanacora, G., & Coric, V. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09123 · Cited by 80
Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin
Poupon-Bejuit, L., Lamoine, S., Pereira, V., Barrière, D. A., Lolignier, S., Giraudet, F., Aissouni, Y., Méleine, M., Prival, L., Richard, D., et al. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2018.07.026 · Cited by 80
How Oxidative Stress Induces Depression?
Ji, N., Lei, M., Chen, Y., Tian, S., Li, C., & Zhang, B. (2023) · ASN NEURO · doi:10.1177/17590914231181037 · Cited by 84
Drug therapy for pain in amyotrophic lateral sclerosis or motor neuron disease
Brettschneider, J., Kurent, J. E., & Ludolph, A. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005226.pub3 · Cited by 66
Chemical-Genetic Screen Identifies Riluzole as an Enhancer of Wnt/β-catenin Signaling in Melanoma
Biechele, T. L., Camp, N. D., Fass, D. M., Kulikauskas, R. M., Robin, N. C., White, B. D., Taraska, C. M., Moore, E. C., Muster, J., Karmacharya, R., et al. (2010) · Chemistry & Biology · doi:10.1016/j.chembiol.2010.08.012 · Cited by 69
A pilot study of hippocampal volume and N-acetylaspartate (NAA) as response biomarkers in riluzole-treated patients with GAD
Abdallah, C. G., Coplan, J. D., Jackowski, A. P., Sato, J. R., Mao, X., Shungu, D. C., & Mathew, S. J. (2012) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2012.05.009 · Cited by 69
Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double‐blind, randomized, placebo‐controlled trial
Anand, A., Gunn, A. D., Barkay, G., Karne, H. S., Nürnberger, J. I., Mathew, S. J., & Ghosh, S. (2012) · Bipolar Disorders · doi:10.1111/j.1399-5618.2011.00971.x · Cited by 69
Enhancement in the Neuroprotective Power of Riluzole Against Cerebral Ischemia Using a Brain Targeted Drug Delivery Vehicle
Verma, S. K., Arora, I., Javed, K., Akhtar, M., & Samim, M. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b01776 · Cited by 63
Opposite Interplay between PPAR Gamma and Canonical Wnt/Beta-Catenin Pathway in Amyotrophic Lateral Sclerosis
Lecarpentier, Y., & Vallée, A. (2016) · Frontiers in Neurology · doi:10.3389/fneur.2016.00100 · Cited by 60
A New Outlook on Mental Illnesses: Glial Involvement Beyond the Glue
Elsayed, M., & Magistretti, P. J. (2015) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2015.00468 · Cited by 62
The Neurobehavioral Pharmacology of Ketamine: Implications for Drug Abuse, Addiction, and Psychiatric Disorders
Trujillo, K. A., Smith, M. L., Sullivan, B., Heller, C. Y., Garcia, C., & Bates, M. L. S. (2011) · ILAR Journal · doi:10.1093/ilar.52.3.366 · Cited by 60
Update on GPCR-based targets for the development of novel antidepressants
Mantas, I., Saarinen, M., Xu, Q., & Svenningsson, P. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01040-1 · Cited by 61
Glutamatergic agents for OCD and related disorders
Pittenger, C. (2015) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-015-0051-8 · Cited by 62
Self-citation
Riluzole in augmentation of fluvoxamine for moderate to severe obsessive–compulsive disorder: R andomized, double‐blind, placebo‐controlled study
Emamzadehfard, S., Kamaloo, A., Paydary, K., Ahmadipour, A., Zeinoddini, A., Ghaleiha, A., Mohammadinejad, P., Zeinoddini, A., & Akhondzadeh, S. (2016) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12394 · Cited by 56
Riluzole combination therapy for moderate-to-severe major depressive disorder: A randomized, double-blind, placebo-controlled trial
Salardini, E., Zeinoddini, A., Mohammadinejad, P., Ardakani, M. R. K., Zahraei, N., Zeinoddini, A., & Akhondzadeh, S. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.01.003 · Cited by 51
Targeting the Modulation of Neural Circuitry for the Treatment of Anxiety Disorders
Farb, D. H., & Ratner, M. H. (2014) · Pharmacological Reviews · doi:10.1124/pr.114.009126 · Cited by 55
Riluzole: a therapeutic strategy in Alzheimer’s disease by targeting the WNT/β-catenin pathway
Vallée, A., Vallée, J.-N., Guillevin, R., & Lecarpentier, Y. (2020) · Aging · doi:10.18632/aging.102830 · Cited by 50
Pharmacotherapeutic Strategies and New Targets in OCD
Pittenger, C. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_204 · Cited by 54
Self-citation
Riluzole activates TRPC5 channels independently of PLC activity
Richter, J. M., Schaefer, M., & Hill, K. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12436 · Cited by 50
Chronic Riluzole Treatment Increases Glucose Metabolism in Rat Prefrontal Cortex and Hippocampus
Chowdhury, G. M. I., Banasr, M., de Graaf, R. A., Rothman, D. L., Behar, K. L., & Sanacora, G. (2008) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2008.78 · Cited by 48
Self-citation
Effect of Gonadal Hormones on Neurotransmitters Implicated in the Pathophysiology of Obsessive-Compulsive Disorder: A Critical Review
Karpinski, M., Mattina, G. F., & Steiner, M. S. (2016) · Neuroendocrinology · doi:10.1159/000453664 · Cited by 49
Riluzole ameliorates learning and memory deficits in Aβ25-35-induced rat model of Alzheimer’s disease and is independent of cholinoceptor activation
Mokhtari, Z., Baluchnejadmojarad, T., Nikbakht, F., Mansouri, M., & Roghani, M. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.12.067 · Cited by 48
A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Comparison Design Trial of Adjunctive Riluzole for Treatment-Resistant Major Depressive Disorder
Mathew, S. J., Gueorguieva, R. V., Brandt, C., D, M. F. M., & Sanacora, G. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.106 · Cited by 46
Self-citation
Riluzole Impairs Cocaine Reinstatement and Restores Adaptations in Intrinsic Excitability and GLT-1 Expression
Sepulveda-Orengo, M. T., Healey, K. L., Kim, R., Auriemma, A. C., Rojas, J. M., Woronoff, N., Hyppolite, R., & Reissner, K. J. (2017) · Neuropsychopharmacology · doi:10.1038/npp.2017.244 · Cited by 45
Electroconvulsive Therapy in a Man With Autism Experiencing Severe Depression, Catatonia, and Self-Injury
Wachtel, L. E., Griffin, M., & Reti, I. M. (2010) · Journal of Ect · doi:10.1097/yct.0b013e3181a744ec · Cited by 45
Hippocampal-Dependent Antidepressant Action of the H3Receptor Antagonist Clobenpropit in a Rat Model of Depression
Femenía, T., Magara, S., DuPont, C. M., & Lindskog, M. (2015) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv032 · Cited by 44
Acute Shift in Glutamate Concentrations Following Experimentally Induced Panic with Cholecystokinin Tetrapeptide—A 3T-MRS Study in Healthy Subjects
Zwanzger, P., Zavorotnyy, M., Gencheva, E., Diemer, J., Kugel, H., Heindel, W. L., Ruland, T., Ohrmann, P., Arolt, V., Domschke, K., et al. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2013.61 · Cited by 41
Efficacy of Glutamate Modulators in Tic Suppression: A Double-Blind, Randomized Control Trial of D-serine and Riluzole in Tourette Syndrome
Lemmon, M. E., Grados, M. A., Kline, T., Thompson, C. B., Ali, S. F., & Singer, H. S. (2015) · Pediatric Neurology · doi:10.1016/j.pediatrneurol.2015.02.002 · Cited by 41
Treatment with the glutamate modulator riluzole prevents early life stress-induced cognitive deficits and impairments in synaptic plasticity in APPswe/PS1dE9 mice
Lesuis, S. L., Kaplick, P. M., Lucassen, P. J., & Krugers, H. J. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.02.023 · Cited by 40
Obsessive-compulsive disorder and related disorders: a comprehensive survey
Fornaro, M., Gabrielli, F., Albano, C., Fornaro, S., Rizzato, S., Mattei, C., Solano, P., Vinciguerra, V., & Fornaro, P. (2009) · Annals of General Psychiatry · doi:10.1186/1744-859x-8-13 · Cited by 46
Synthesis and structure–activity relationship study of substituted caffeate esters as antinociceptive agents modulating the TREK-1 channel
Rodrigues, N., Bennis, K., Vivier, D., Pereira, V., Chatelain, F. C., Chapuy, E., Deokar, H. S., Busserolles, J., Lesage, F., Eschalier, A., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.049 · Cited by 39
Riluzole produces distinct anxiolytic-like effects in rats without the adverse effects associated with benzodiazepines
Sugiyama, A., Saitoh, A., Iwai, T., Takahashi, K., Yamada, M., Sasaki-Hamada, S., Oka, J.-I., Inagaki, M., & Yamada, M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.02.012 · Cited by 38
Efficacy and tolerability of riluzole in psychiatric disorders: A systematic review and preliminary meta-analysis
de Boer, J. N., Vingerhoets, C., Hirdes, M., McAlonan, G. M., Amelsvoort, T. V., & Zinkstok, J. R. (2019) · Psychiatry Research · doi:10.1016/j.psychres.2019.06.020 · Cited by 38
Beyond the therapeutic shackles of the monoamines: new mechanisms in bipolar disorder biology
Data-Franco, J., Singh, A., Popovic, D., Ashton, M., Berk, M., Vieta, E., Figueira, M. L., & Dean, O. M. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.09.004 · Cited by 38
Glutamate Modulators in the Treatment of Obsessive-Compulsive Disorder
Pittenger, C. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150602-06 · Cited by 41
Self-citation
Neurotransmitter signaling pathways required for normal development inXenopus laevisembryos: a pharmacological survey screen
Sullivan, K. G., & Levin, M. G. (2016) · Journal of Anatomy · doi:10.1111/joa.12467 · Cited by 35
L-Carnosine combination therapy for major depressive disorder: A randomized, double-blind, placebo-controlled trial
Araminia, B., Shalbafan, M., Mortezaei, A., Shirazi, E., Ghaffari, S., Sahebolzamani, E., Mortazavi, S. H., Shariati, B., Ardebili, M. E., Aqamolaei, A., et al. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.02.020 · Cited by 32
Riluzole increases glutamate uptake by cultured C6 astroglial cells
Dall'Igna, O. P. P., Bobermin, L. D., Souza, D. O., & Quincozes‐Santos, A. (2013) · International Journal of Developmental Neuroscience · doi:10.1016/j.ijdevneu.2013.06.002 · Cited by 31
A 10-Week Memantine Treatment in Bipolar Depression: A Case Report. Focus on Depressive Symptomatology, Cognitive Parameters and Quality of Life
Strzelecki, D., Tabaszewska, A., Barszcz, Z., Józefowicz, O., Kropiwnicki, P., & Rabe‐Jabłońska, J. (2013) · Psychiatry Investigation · doi:10.4306/pi.2013.10.4.421 · Cited by 29
Antidepressive and anxiolytic effects of ostruthin, a TREK-1 channel activator
Joseph, A., Thủy, T. T. T., Thanh, L. T., & Okada, M. (2018) · PLoS ONE · doi:10.1371/journal.pone.0201092 · Cited by 29
Autonomic modulation of ventricular electrical activity: recent developments and clinical implications
van Weperen, V. Y. H., Vos, M. A., & Ajijola, O. A. (2021) · Clinical Autonomic Research · doi:10.1007/s10286-021-00823-4 · Cited by 29
Riluzole: a potential therapeutic intervention in human brain tumor stem-like cells
Sperling, S., Aung, T., Martin, S., Rohde, V., & Ninković, M. (2017) · Oncotarget · doi:10.18632/oncotarget.18043 · Cited by 32
Pain and the Brain: Diabetic Neuropathic Pain
Jain, R. K. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.0808e22 · Cited by 27
The Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.11.005 · Cited by 26
Self-citation
Regioselective Synthesis, Antimicrobial Evaluation and QSAR Studies of Some 3‐Aryl‐1‐heteroarylindeno[1,2‐c]pyrazol‐4(1H)‐ones
Mor, S., Mohil, R., Nagoria, S., Kumar, A., Lal, K., Kumar, D., & Singh, V. (2016) · Journal of Heterocyclic Chemistry · doi:10.1002/jhet.2710 · Cited by 24
Design, Synthesis and Biological Activities of (Thio)Urea Benzothiazole Derivatives
Mendieta‐Wejebe, J. E., Rosales‐Hernández, M. C., Martínez, I. I. P., Garcı́a-Báez, E. V., & Cruz, A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119488 · Cited by 23
Exploring the impact of ketogenic diet on multiple sclerosis: obesity, anxiety, depression, and the glutamate system
Ortí, J. E. D. L. R., Cuerda‐Ballester, M., Sanchis-Sanchis, C. E., Lajara-Romance, J. M., Navarro-Illana, E., & García-Pardo, M. P. (2023) · Frontiers in Nutrition · doi:10.3389/fnut.2023.1227431 · Cited by 25
Riluzole decreases flexion withdrawal reflex but not voluntary ankle torque in human chronic spinal cord injury
Theiss, R., Hornby, T. G., Rymer, W. Z., & Schmit, B. D. (2011) · Journal of Neurophysiology · doi:10.1152/jn.00570.2010 · Cited by 23
Longer-term open-label study of adjunctive riluzole in treatment-resistant depression
Sakurai, H., Dording, C., Yeung, A., Foster, S., Jain, F., Chang, T., Trinh, N.-H., Bernard, R., Boyden, S., Iqbal, S. Z., et al. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.06.065 · Cited by 20
“Its mechanism of action is thought to be inhibition of presynaptic release of glutamate via inactivation of voltage-dependent sodium channels on glutamatergic nerve terminals (Pittenger et al., 2008; Doble, 1996).”
Background
Effects of persistent sodium current blockade in respiratory circuits depend on the pharmacological mechanism of action and network dynamics
Phillips, R. S., & Rubin, J. E. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1006938 · Cited by 22
Benzothiazoles from Condensation of o-Aminothiophenoles with Carboxylic Acids and Their Derivatives: A Review
Garcı́a-Báez, E. V., Martínez, I. I. P., Cach, F. T., & Cruz, A. (2021) · Molecules · doi:10.3390/molecules26216518 · Cited by 22
Passiflora actinia hydroalcoholic extract and its major constituent, isovitexin, are neuroprotective against glutamate-induced cell damage in mice hippocampal slices
dos Santos, K. C., Borges, T. V., Olescowicz, G., Ludka, F. K., Santos, C. A. D. M., & Molz, S. (2016) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.12512 · Cited by 21
Inflammation Effects on Glutamate as a Pathway to Neuroprogression in Mood Disorders
Haroon, E., & Miller, A. H. (2017) · Modern trends in psychiatry · doi:10.1159/000470805 · Cited by 22
Inflammation: opportunities for treatment stratification among individuals diagnosed with mood disorders
Subramaniapillai, M., Carmona, N. E., Rong, C., & McIntyre, R. S. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.1/rmcintyre · Cited by 21
Riluzole-induced glial cell line-derived neurotrophic factor production is regulated through fibroblast growth factor receptor signaling in rat C6 glioma cells
Okada‐Tsuchioka, M., Hisaoka, K., Yano, R., Shibasaki, C., Kajiatani, N., & Takebayashi, M. (2011) · Brain Research · doi:10.1016/j.brainres.2011.01.100 · Cited by 21
Teaching Students With Obsessive-Compulsive Disorder
Leininger, M., Dyches, T. T., Prater, M. A., & Heath, M. A. (2010) · Intervention in School and Clinic · doi:10.1177/1053451209353447 · Cited by 20

Authors: Pittenger, C., Coric, V., Banasr, M., Bloch, M., Krystal, J. H., & Sanacora, G.
Affiliations: Yale University (US)
Corresponding author: Pittenger, Christopher
ORCID: Pittenger, Christopher
Banasr, Mounira
Bloch, Michael
Krystal, John H
Sanacora, Gerard
Venue: CNS Drugs
Publisher: Springer Science and Business Media LLC
Published: 2008
Volume: 22
Issue: 9
Pages: 761-786
ISSN: 1172-7047 (ISSN-L)
DOI: 10.2165/00023210-200822090-00004
OpenAlex: W1967308562
Cited by: 177
References: 205
Citations by year: 2026: 5 · 2025: 6 · 2024: 5 · 2023: 12 · 2022: 7 · 2021: 11 · 2020: 6 · 2019: 6 · 2018: 7 · 2017: 10 · 2016: 17 · 2015: 12 · 2014: 9 · 2013: 13 · 2012: 13
FWCI: 1.33
Type: journal article
Language: en
Open access: closed
Locations: CNS Drugs (publishedVersion)
PubMed (publishedVersion)
Funders: National Institute of Mental Health (T32 MH 19961, T32MH019961)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
Keywords: riluzole, mood disorders, anxiety disorders, obsessive-compulsive disorder, depression, bipolar disorder, generalized anxiety disorder, glutamatergic neurotransmission, voltage-gated sodium channel inhibition, neuroprotection, trichotillomania, self-harm, borderline personality disorder, drug tolerability, liver function monitoring
MeSH terms: Animals, Anxiety Disorders, Humans, Models, Biological, Nervous System Diseases, Receptors, Glutamate, Excitatory Amino Acid Antagonists, Riluzole, Mood Disorders

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Riluzole in the Treatment of Mood and Anxiety Disorders

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks